Percutaneous image-guided cryoablation of painful bone metastases: A single institution experience.


Journal

Orthopaedics & traumatology, surgery & research : OTSR
ISSN: 1877-0568
Titre abrégé: Orthop Traumatol Surg Res
Pays: France
ID NLM: 101494830

Informations de publication

Date de publication:
04 2019
Historique:
received: 19 12 2017
revised: 16 07 2018
accepted: 07 01 2019
pubmed: 13 3 2019
medline: 3 3 2020
entrez: 13 3 2019
Statut: ppublish

Résumé

Bone metastases are frequently painful and may lead to various complications that can affect quality of life. While external beam radiation therapy is the standard first-line treatment, 20-30% of patients do not experience sufficient pain relief. Cryoablation is increasingly being used for the treatment of musculoskeletal metastases. The purpose of our retrospective study was to analyze pain relief and local disease control after percutaneous image-guided cryoablation (PCA) therapy of painful bone metastases. Sixteen patients treated with PCA for painful bone metastases (n=18) over a 5-year period (from June 2011 to June 2016) were retrospectively reviewed. Five patients also benefited from long bone fixation because of an impending fracture. We analyzed the impact of treatment on pain relief, using a numerical rating scale (NRS), and local disease control. The mean follow-up period was 12 months (range, 1.5-39 months). At last oncological outpatient consultation, 75% (12/16) of patients had good pain relief, while 63% (10/16) had locally stable disease or no local recurrence of the treated bone metastases. The mean NRS score decreased significantly from 3.3 to 1.2 after PCA (p=0.0024). The five patients with concomitant long bone fixation all had satisfactory pain relief at the last follow-up visit. PCA is a safe and valid treatment option for pain and local disease control in cases of painful bone metastases after failed standard first-line therapy. This technique can also be effectively associated to prophylactic long bone fixation and may allow for easier rehabilitation protocols when treating weight-bearing bones. IV, Retrospective case series.

Sections du résumé

BACKGROUND
Bone metastases are frequently painful and may lead to various complications that can affect quality of life. While external beam radiation therapy is the standard first-line treatment, 20-30% of patients do not experience sufficient pain relief. Cryoablation is increasingly being used for the treatment of musculoskeletal metastases. The purpose of our retrospective study was to analyze pain relief and local disease control after percutaneous image-guided cryoablation (PCA) therapy of painful bone metastases.
MATERIALS AND METHODS
Sixteen patients treated with PCA for painful bone metastases (n=18) over a 5-year period (from June 2011 to June 2016) were retrospectively reviewed. Five patients also benefited from long bone fixation because of an impending fracture. We analyzed the impact of treatment on pain relief, using a numerical rating scale (NRS), and local disease control.
RESULTS
The mean follow-up period was 12 months (range, 1.5-39 months). At last oncological outpatient consultation, 75% (12/16) of patients had good pain relief, while 63% (10/16) had locally stable disease or no local recurrence of the treated bone metastases. The mean NRS score decreased significantly from 3.3 to 1.2 after PCA (p=0.0024). The five patients with concomitant long bone fixation all had satisfactory pain relief at the last follow-up visit.
CONCLUSION
PCA is a safe and valid treatment option for pain and local disease control in cases of painful bone metastases after failed standard first-line therapy. This technique can also be effectively associated to prophylactic long bone fixation and may allow for easier rehabilitation protocols when treating weight-bearing bones.
LEVEL OF EVIDENCE
IV, Retrospective case series.

Identifiants

pubmed: 30858041
pii: S1877-0568(19)30029-5
doi: 10.1016/j.otsr.2019.01.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

369-374

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Nicolas Gallusser (N)

Lausanne University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland.

Patrick Goetti (P)

Lausanne University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland.

Fabio Becce (F)

Lausanne University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland.

Frédéric Vauclair (F)

Lausanne University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland.

Hannes A Rüdiger (HA)

Lausanne University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland.

Pierre E Bize (PE)

Lausanne University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland.

Stéphane Cherix (S)

Lausanne University Hospital, 46, rue du Bugnon, CH-1011 Lausanne, Switzerland. Electronic address: stephane.cherix@chuv.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH